Showing results (2021-2030 of 2,232) with videos related to
Sort By:
Pageof 224
Journal of Hematology & Oncology|December 7, 2025
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapyYi-Long Wu, Lin Wu, Nan Bi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2018
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR MutationShan Su, Zhong-Yi Dong, Zhi Xie, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 3, 2018
Association of injury pattern and entrapment location inside damaged buildings in the 2016 Taiwan earthquakeShih-Tien Pan, Ya-Yun Cheng, Chen-Long Wu, et al.The New England Journal of Medicine|December 14, 2016
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung CancerTony S Mok, Yi-Long Wu, Myung-Ju Ahn, et al.The Lancet. Respiratory Medicine|December 19, 2022
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN studyBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2011
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)Masahiro Fukuoka, Yi-Long Wu, Sumitra Thongprasert, et al.The New England Journal of Medicine|August 21, 2009
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaTony S Mok, Yi-Long Wu, Sumitra Thongprasert, et al.Journal of Cancer Research and Clinical Oncology|May 5, 2007
KDR expression is associated with the stage and cigarette smoking of the patients with lung cancerShe-Juan An, Qiang Nie, Zhi-Hong Chen, et al.Eclinicalmedicine|June 8, 2026
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in ChinaChao Zhang, Ben-Yuan Jiang, Li-Xu Yan, et al.Cancer Medicine|May 2, 2026
Age-Associated Targetable Genomic Alterations and PD-L1 Expression in 2509 Patients With Pulmonary Ground-Glass OpacitiesWen-Fang Tang, Si-Qi Huang, Yi-Duo Lin, et al.Pageof 224